Contemporary Management and Research Directions in Advanced Heart Failure: Where Are We Going?

Congestive Heart Failure

Volumn 17, Issue 5, 2011, Pages 241-247

  Kamouh, Abdallah ^a   Francis, Gary S ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (4 BENZHYDRYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY] 1H INDOLE 2 CARBONITRILE; ADENOSINE RECEPTOR BLOCKING AGENT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARDIOVASCULAR AGENT; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ETOMOXIR; FUROSEMIDE; INOTROPIC AGENT; IRON DERIVATIVE; ISTAROXIME; IVABRADINE; LEVOSIMENDAN; LY 333612; NESIRITIDE; RANOLAZINE; RELAXIN; ROLOFYLLINE; TOLVAPTAN; TRIMETAZIDINE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ACUTE HEART FAILURE; ADVANCED HEART FAILURE; APNEA; ASSISTED CIRCULATION; CLINICAL RESEARCH; CONTINUOUS INFUSION; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; HEALTH CARE COST; HEART FAILURE; HEART FUNCTION; HEART TRANSPLANTATION; HEMODYNAMICS; HOSPICE CARE; HUMAN; HYPONATREMIA; MEDICAL TECHNOLOGY; PALLIATIVE THERAPY; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STEM CELL TRANSPLANTATION; SYSTOLIC HEART FAILURE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; ULTRAFILTRATION;

BIOMEDICAL RESEARCH; HEART FAILURE; HUMANS;

EID: 80052677303     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2011.00243.x     Document Type: Review

References (55)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:391-479.
2. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2010;121:e46-e215.
3. Metra M, Ponikowski P, Dickstein K, et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007;9:684-694.
4. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
5. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49:1733-1739.
6. Sugiura T, Takase H, Toriyama T, et al. Circulating levels of myocardial proteins predict future deterioration of congestive heart failure. J Card Fail. 2005;11:504-509.
7. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) Randomized Trial. JAMA. 2009;301:383-392.
8. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:2148-2159.
9. Ritzema J, Troughton R, Melton I, et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation. 2010;121:1086-1095.
10. Bourge RC, Abraham WT, Adamson PB, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF Study. J Am Coll Cardiol. 2008;51:1073-1079.
11. Verdejo HE, Castro PF, Concepcion R, et al. Comparison of a radiofrequency-based wireless pressure sensor to Swan-Ganz catheter and echocardiography for ambulatory assessment of pulmonary artery pressure in heart failure. J Am Coll Cardiol. 2007;50:2375-2382.
12. Castro PF, Concepcion R, Bourge RC, et al. A wireless pressure sensor for monitoring pulmonary artery pressure in advanced heart failure: initial experience. J Heart Lung Transplant. 2007;26:85-88.
13. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery hemodynamic monitoring in chronic heart failure: a randomized controlled trial. Lancet. 2011;377:658-666.
14. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure: Vesnarinone Trial Investigators. N Engl J Med. 1998;339:1810-1816.
15. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468-1475.
16. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422-1432.
17. Steinberg MI, McCall E, Mest HJ, et al. Cardiac sodium channels as targets for new inotropic agents. Heart Fail Rev. 1998;2:173-193.
18. Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind study. Lancet. 2002;360:196-202.
19. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007;297:1883-1891.
20. Schwinger R, Böhm M, Mittmann C, et al. Evidence for a sustained effectiveness of sodium-channel activators in failing human myocardium. J Mol Cell Cardiol. 1991;23:461-471.
21. Flesch M, Erdmann E. Na+ channel activators as positive inotropic agents for the treatment of chronic heart failure. Cardiovasc Drugs Ther. 2001;15:379-386.
22. Gheorghiade M, Blair JE, Filippatos GS, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008;51:2276-2285.
23. Morrow DA, Givertz MM. Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease. Circulation. 2005;112:3218-3221.
24. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373:1429-1439.
25. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritidevs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
26. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.
27. Hernandez AF, O'Connor CM, Starling RC, et al. Rationale and design of the Acute Study of Clinical effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J. 2009;157:271-277.
28. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. For the efficacy of vasopressin antagonism in heart failure outcome study with Tolvaptan I. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319-1331.
29. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963-1971.
30. Teerlink JR, McMurray JJ, Bourge RC, et al. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J. 2005;150:46-53.
31. Yancy CW, Krum H, Massie BM, et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circ Heart Fail. 2008;1:9-16.
32. 1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363:1419-1428.
33. Felker GM, Pang PS, Adams KF, et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. International AHFS Working Group. Circ Heart Fail. 2010;3:314-325.
34. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436-2448.
35. Van der Meer P, Groenveld HF, Januzzi JL Jr, et al. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart. 2009;95:1309-1314.
36. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. SHIFT Investigators. Lancet. 2010;376:875-885.
37. Costanzo MR, Saltzberg MT, Jessup M, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Card Fail. 2010;16:277-284.
38. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805.
39. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251.
40. Slaughter MS, Myers TJ. Transcutaneous energy transmission for mechanical circulatory support systems: history, current status, and future prospects. J Card Surg. 2010;25:484-489.
41. Mehta SM, Pae WE Jr, Rosenberg G, et al. The LionHeart LVD-2000: a completely implanted left ventricular assist device for chronic circulatory support. Ann Thorac Surg. 2001;71(suppl):S156-S161.
42. Baldwin JT, Mann DL. NHLBI's program for VAD therapy for moderately advanced heart failure: the REVIVE-IT pilot trial. J Card Fail. 2010;16:855-858.
43. Legget ME, Peters WS, Milsom FP, et al. Extra-aortic balloon counterpulsation: an intraoperative feasibility study. Circulation. 2005;112(suppl 9):I26-I31.
44. Kirklin JK, Naftel DC, Stevenson LW, et al. INTERMACS database for durable devices for circulatory support: first annual report. J Heart Lung Transplant. 2008;27:1065-1072.
45. Vega JD, Moore J, Murray S, et al. Hearttransplantation in the United States, 1998-2007. Am J Transplant. 2009;9:932-941.
46. Cooper DKC, Keogh A, Brink J, et al. Report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation: the present status of xenotransplantation and its potential role in the treatment of end-stage cardiac and pulmonary diseases. J Heart Lung Transplant. 2000;19:1125-1165.
47. Mehra MR, Parameshwar J. Gene expression profiling and cardiac allograft rejection monitoring: is IMAGE just a mirage? J Heart Lung Transplant. 2010;29:599-602.
48. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277-2286.
49. Anversa P, Kajstura J, Leri A, et al. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation. 2006;113:1451-1463.
50. Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary stem cell transplantation in 191 patients with chronic heart failure: the STAR-heart study. Eur J Heart Fail. 2010;12:721-729.
51. Heldman AW, Zambrano JP, Hare JM. Cardiac stem cell therapy: where are we in 2011? J Am Coll Cardiol. 2011;57:466-468.
52. Porrello ER, Mahmoud AI, Simpson E, et al. Transient regenerative potential of the neonatal mouse heart. Science. 2011;331:1078-1080.
53. Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell. 2010;142:375-386.
54. Suckau L, Fechner H, Chemaly E, et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation. 2009;119:1241-1252.
55. Kawase Y, Ladage D, Hajjar RJ, et al. Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol. 2011;57:1169-1180.